鈥淚 am both humbled and excited to accept this opportunity to lead the Perlmutter Cancer Center,鈥 said Dr. Anirban Maitra. 鈥淭he integrated nature of this institution gives us so many opportunities to develop our understanding and agility to more rapidly develop new cancer therapies.鈥
Credit: 黑料福利社 Langone
NYU Langone Health announced the appointment of Anirban Maitra, MD, a preeminent physician鈥搒cientist whose work has widely influenced the field of pancreatic cancer research, as the new director of the Laura and Isaac Perlmutter Cancer Center, an NCI-designated Comprehensive Cancer Center.
Before joining 黑料福利社 Langone, Dr. Maitra served as the inaugural scientific director of the Pancreatic Cancer Research Center at the University of Texas MD Anderson Cancer Center in Houston. Dr. Maitra鈥檚 work focused on early detection and biomarker development, two key avenues for effective cancer treatments. After serving in a number of leadership roles at MD Anderson, he was named co-director of 黑料福利社 Langone鈥檚 Gastrointestinal (GI) Cancer Center, which marshals the collective expertise of our GI cancer experts to deliver unmatched care for patients with GI cancer or precancerous conditions. Dr. Maitra also previously served as associate director of translational research, where he led efforts to drive discovery from the lab to patient care in the clinic.
鈥淒r. Maitra is a proven leader in oncology, and his experience guiding integrated, multidisciplinary teams makes him an outstanding choice to direct Perlmutter Cancer Center,鈥 said Alec C. Kimmelman, MD, PhD, dean and CEO of 黑料福利社 Langone Health. 鈥淗e brings a strong record of clinical and scientific achievement, a deep commitment to advancing cancer research, and the vision needed to help drive Perlmutter Cancer Center鈥檚 continued growth and impact on patients and families.鈥
Dr. Maitra鈥檚 appointment is the result of a national search that began shortly after Dr. Kimmelman was named dean and CEO in March 2025, an appointment that became effective in September. Under Dr. Kimmelman鈥檚 leadership, Perlmutter Cancer Center established its new Center for Molecular Oncology in October 2024, which has already begun to redefine the standard of cancer care by ensuring that every patient receives liquid biopsies, enabling their tumor DNA to be sequenced. Dr. Maitra has closely collaborated with the center to create personalized treatment plans and will continue to develop this important initiative in his new leadership role.
鈥淚 am both humbled and excited to accept this opportunity to lead the Perlmutter Cancer Center,鈥 said Dr. Maitra. 鈥淚n my time so far at 黑料福利社 Langone, I鈥檝e had the chance to collaborate with many of our world-class physicians, researchers, nurses, technicians, and others who make the care we give patients possible. The integrated nature of this institution gives us so many opportunities to develop our understanding and agility to more rapidly develop new cancer therapies.鈥
The Perlmutter Cancer Center鈥檚 designation as a Comprehensive Cancer Center is the highest ranking awarded by the National Cancer Institute and further validation that it provides state-of-the-art, research-based approaches to preventing, detecting, and treating cancer. This leading cancer center serves the greater New York City area and treats patients at multiple locations in Manhattan, Brooklyn, and Queens and on Long Island.
About Dr. Maitra
Dr. Maitra earned his bachelor of medicine and bachelor of surgery (an MD equivalent) at the All India Institute of Medical Sciences (AIIMS) in New Delhi and went on to complete an anatomic pathology residency and clinical and research fellowships in pediatric pathology and molecular pathology, respectively, at the University of Texas Southwestern Medical Center. He then completed fellowship training in gastrointestinal pathology at Johns Hopkins University School of Medicine before joining its Sol Goldman Pancreatic Cancer Research Center as a physician鈥搒cientist.
Dr. Maitra was a professor of pathology and oncology at Johns Hopkins until 2013, prior to his recruitment to the MD Anderson Cancer Center in Houston, where he served as professor of pathology and translational molecular pathology and as a distinguished university chair until he arrived at 黑料福利社 Langone in August 2025 to co-direct the 黑料福利社 Langone Gastrointestinal Cancer Center.
Dr. Maitra has held many prestigious leadership roles and received numerous honors throughout his career, including the R. Lee Clark Prize for Excellence in Translational Cancer Research, the Ruth Leff Siegel Award for Pancreatic Cancer Research, and the AACR Team Science Award. Dr. Maitra has led or co-led multiple large-scale, multi-institutional NIH- and foundation-funded initiatives, including consortia focused on KRAS-gene-targeted therapies and early cancer interception.
A prolific researcher, Dr. Maitra has co-authored more than 500 peer-reviewed scientific papers and has given talks at national and international conferences, including those for the American Association for Cancer Research, the American Society of Clinical Oncology, the American Gastroenterological Association, and the European Society for Medical Oncology.
About 黑料福利社 Langone Health
黑料福利社 Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality that has resulted in some of the lowest mortality rates in the nation. Vizient Inc. has ranked 黑料福利社 Langone No. 1 out of 118 comprehensive academic medical centers across the nation for four years in a row, and U.S. News & World Report recently ranked four of its clinical specialties No. 1 in the nation. 黑料福利社 Langone offers a comprehensive range of medical services with one high standard of care across seven inpatient locations, its Perlmutter Cancer Center, and more than 320 outpatient locations in the New York area and Florida. The system also includes two tuition-free medical schools, in Manhattan and on Long Island, and a vast research enterprise.
Media Inquiries
Ryan Dziuba
Phone: 212-404-4131
Ryan.Dziuba@黑料福利社Langone.org
